financetom
Business
financetom
/
Business
/
India Inc staring at 15% profit erosion in FY21, 10% revenue decline: Crisil
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India Inc staring at 15% profit erosion in FY21, 10% revenue decline: Crisil
Apr 30, 2020 6:12 AM

India Inc is staring at a bleak and forgettable fiscal year FY21, which is likely to see a 10 percent fall in revenues and at least 15 percent erosion in profits due to the COVID-19 pandemic, domestic ratings agency Crisil said on Thursday.

Share Market Live

NSE

Loan servicing can become difficult as a result of the troubles, its research wing said, estimating banks' non-performing assets (NPAs) to rise by up to 2 percentage points to 11.5 percent, and credit growth to slow down to 2 percent.

At present, the country is under a 40-day lockdown till May 3, and there are indications of it being gradually withdrawn.

Crisil estimated one month of the lockdown to shave off 3 percentage points from the gross domestic product (GDP) and warned that its base case of 1.8 per cent growth for FY21 may fall to zero if the lockdown continues.

Its chief economist Dharmakirti Joshi said up to 4 percent of the GDP will be lost permanently as a result of the crisis, which will lead to scores getting unemployed.

He said the fiscal support worth Rs 1.7 lakh crore announced till now is inadequate to fight the crisis.

Crisil expects a doubling of the stimulus to Rs 3.5 lakh crore with a focus on the industries segment in the second phase. Apart from the spending measures, there can be others like loan guarantees also, it said.

Joshi explained that countries having more fiscal space can afford to have longer lockdowns, while those like India with limited room will have to gradually open up to support the economy, and added that the containment measures should ease off by June.

However, the agency seemed to suggest that India Inc will be badly impacted due to the crisis.

This is unprecedented and the numbers that we are estimating are historic, which you would like to forget sooner, Crisil Research's senior director Prasad Koparkar said.

Koparkar said Crisil did an analysis of 800 firms across sectors and came out with estimates for the fiscal 2020-21.

It expects India Inc's revenue growth to fall 8-10 percent in the base case of 1.8 percent growth and slide further to 12-15 percent if the GDP is stagnant.

The more pronounced impact will be on profitability as it expects a 15-18 percent decline in operating profit margins in the base case, which can go up to 30 percent in the downside scenario.

As a result of this, credit metrics are set to weaken during the fiscal, Crisil said, pointing out that the level of the Rs 16 lakh crore corporate debt that stands the risk of slipping into being stressed will go up to 32 per cent from the earlier level of 22 per cent.

Koparkar said bank credit growth will slow down to 2-3 percent and the retail segment, which had held on in the last few years, will also slow down as housing, auto and commercial vehicle sales suffer.

The heightened stress and the slow credit growth will take the overall NPAs to up to 11.5 percent, a level last seen in FY18 after the asset quality review of the Reserve Bank of India (RBI).

The NPAs will be higher both on fresh slippages and also slower resolutions through mechanisms like National Company Law Tribunals, it said.

Without giving a number, Koparkar said NPAs in the retail segment will also rise as the spectre of unemployment plays out.

From a sectoral perspective, it said auto components, real estate, gems and jewellery, construction, airlines, textiles, poultry and meat business will suffer the most, while pharma, telecom and direct to home players in media will be the least impacted.

For telecom, the research is estimating a double-digit revenue growth on the back of the 40 percent hike in tariffs last year, Koparkar said.

First Published:Apr 30, 2020 3:12 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says
Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says
Mar 19, 2026
12:10 PM EDT, 03/19/2026 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) received further validation for its oral peptide platform with the US Food Drug Administration approval of Icotyde as treatment for psoriasis, Wedbush Securities said in a note Thursday. The investment firm said the regulatory approval was expected after Protagonist and partner Johnson & Johnson (JNJ), which holds global...
Apple fends off bid for new Apple Watch import ban at US trade tribunal 
Apple fends off bid for new Apple Watch import ban at US trade tribunal 
Mar 19, 2026
WASHINGTON, March 19 (Reuters) - A U.S. trade tribunal preliminarily ruled that Apple's ( AAPL ) current Apple Watches do not infringe patents owned by Masimo ( MASI ), rejecting the medical-monitoring company's bid for a renewed import ban on the tech giant's smartwatches. Apple ( AAPL ) altered its watches to circumvent an import ban that the U.S. International...
Actelis Networks (ASNS) Stock Is Surging Thursday: What's Driving The Action?
Actelis Networks (ASNS) Stock Is Surging Thursday: What's Driving The Action?
Mar 19, 2026
Actelis Networks Inc ( ASNS ) stock is trading higher Thursday, even after the company reported a wider-than-expected fourth-quarter loss, as investors appeared to focus on a sharp sequential revenue rebound, improving gross margin and an expanded share repurchase program. Here’s what investors need to know. Actelis Networks ( ASNS ) stock is charging ahead with explosive momentum. What’s behind...
Novo Nordisk Says FDA Approves Weight Loss Drug Wegovy HD
Novo Nordisk Says FDA Approves Weight Loss Drug Wegovy HD
Mar 19, 2026
12:13 PM EDT, 03/19/2026 (MT Newswires) -- Novo Nordisk ( NVO ) said Thursday the US Food and Drug Administration has approved its once-weekly Wegovy HD injection to lower excess body weight and sustain long-term weight loss. The accelerated approval was supported by late-stage trial data where the 7.2-milligram dose produced an average of 21% weight loss in obese participants,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved